Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

34 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial.
Gottlieb RL, Nirula A, Chen P, Boscia J, Heller B, Morris J, Huhn G, Cardona J, Mocherla B, Stosor V, Shawa I, Kumar P, Adams AC, Van Naarden J, Custer KL, Durante M, Oakley G, Schade AE, Holzer TR, Ebert PJ, Higgs RE, Kallewaard NL, Sabo J, Patel DR, Klekotka P, Shen L, Skovronsky DM. Gottlieb RL, et al. Among authors: kallewaard nl. JAMA. 2021 Feb 16;325(7):632-644. doi: 10.1001/jama.2021.0202. JAMA. 2021. PMID: 33475701 Free PMC article. Clinical Trial.
Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19.
Dougan M, Nirula A, Azizad M, Mocherla B, Gottlieb RL, Chen P, Hebert C, Perry R, Boscia J, Heller B, Morris J, Crystal C, Igbinadolor A, Huhn G, Cardona J, Shawa I, Kumar P, Adams AC, Van Naarden J, Custer KL, Durante M, Oakley G, Schade AE, Holzer TR, Ebert PJ, Higgs RE, Kallewaard NL, Sabo J, Patel DR, Dabora MC, Klekotka P, Shen L, Skovronsky DM; BLAZE-1 Investigators. Dougan M, et al. Among authors: kallewaard nl. N Engl J Med. 2021 Oct 7;385(15):1382-1392. doi: 10.1056/NEJMoa2102685. Epub 2021 Jul 14. N Engl J Med. 2021. PMID: 34260849 Free PMC article. Clinical Trial.
Endogenous Antibody Responses to SARS-CoV-2 in Patients With Mild or Moderate COVID-19 Who Received Bamlanivimab Alone or Bamlanivimab and Etesevimab Together.
Zhang L, Poorbaugh J, Dougan M, Chen P, Gottlieb RL, Huhn G, Beasley S, Daniels M, Ngoc Vy Trinh T, Crisp M, Freitas JJ, Vaillancourt P, Patel DR, Nirula A, Kallewaard NL, Higgs RE, Benschop RJ. Zhang L, et al. Among authors: kallewaard nl. Front Immunol. 2021 Dec 9;12:790469. doi: 10.3389/fimmu.2021.790469. eCollection 2021. Front Immunol. 2021. PMID: 34956222 Free PMC article. Clinical Trial.
Relationship between gene expression patterns from nasopharyngeal swabs and serum biomarkers in patients hospitalized with COVID-19, following treatment with the neutralizing monoclonal antibody bamlanivimab.
Sims JT, Poorbaugh J, Chang CY, Holzer TR, Zhang L, Engle SM, Beasley S, Doman TN, Naughton L, Higgs RE, Kallewaard N, Benschop RJ. Sims JT, et al. J Transl Med. 2022 Mar 18;20(1):134. doi: 10.1186/s12967-022-03345-3. J Transl Med. 2022. PMID: 35303909 Free PMC article. Clinical Trial.
The anti-SARS-CoV-2 monoclonal antibody bamlanivimab minimally affects the endogenous immune response to COVID-19 vaccination.
Benschop RJ, Tuttle JL, Zhang L, Poorbaugh J, Kallewaard NL, Vaillancourt P, Crisp M, Trinh TNV, Freitas JJ, Beasley S, Daniels M, Haustrup N, Higgs RE, Nirula A, Cohen MS, Marovich M. Benschop RJ, et al. Among authors: kallewaard nl. Sci Transl Med. 2022 Jul 27;14(655):eabn3041. doi: 10.1126/scitranslmed.abn3041. Epub 2022 Jul 27. Sci Transl Med. 2022. PMID: 35679357 Free PMC article. Clinical Trial.
LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants.
Westendorf K, Žentelis S, Wang L, Foster D, Vaillancourt P, Wiggin M, Lovett E, van der Lee R, Hendle J, Pustilnik A, Sauder JM, Kraft L, Hwang Y, Siegel RW, Chen J, Heinz BA, Higgs RE, Kallewaard NL, Jepson K, Goya R, Smith MA, Collins DW, Pellacani D, Xiang P, de Puyraimond V, Ricicova M, Devorkin L, Pritchard C, O'Neill A, Dalal K, Panwar P, Dhupar H, Garces FA, Cohen CA, Dye JM, Huie KE, Badger CV, Kobasa D, Audet J, Freitas JJ, Hassanali S, Hughes I, Munoz L, Palma HC, Ramamurthy B, Cross RW, Geisbert TW, Menachery V, Lokugamage K, Borisevich V, Lanz I, Anderson L, Sipahimalani P, Corbett KS, Yang ES, Zhang Y, Shi W, Zhou T, Choe M, Misasi J, Kwong PD, Sullivan NJ, Graham BS, Fernandez TL, Hansen CL, Falconer E, Mascola JR, Jones BE, Barnhart BC. Westendorf K, et al. Among authors: kallewaard nl. Cell Rep. 2022 May 17;39(7):110812. doi: 10.1016/j.celrep.2022.110812. Epub 2022 Apr 25. Cell Rep. 2022. PMID: 35568025 Free PMC article.
The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in nonhuman primates and has an extended half-life in humans.
Loo YM, McTamney PM, Arends RH, Abram ME, Aksyuk AA, Diallo S, Flores DJ, Kelly EJ, Ren K, Roque R, Rosenthal K, Streicher K, Tuffy KM, Bond NJ, Cornwell O, Bouquet J, Cheng LI, Dunyak J, Huang Y, Rosenbaum AI, Pilla Reddy V, Andersen H, Carnahan RH, Crowe JE Jr, Kuehne AI, Herbert AS, Dye JM, Bright H, Kallewaard NL, Pangalos MN, Esser MT. Loo YM, et al. Among authors: kallewaard nl. Sci Transl Med. 2022 Mar 9;14(635):eabl8124. doi: 10.1126/scitranslmed.abl8124. Epub 2022 Mar 9. Sci Transl Med. 2022. PMID: 35076282 Free PMC article.
Potently neutralizing and protective human antibodies against SARS-CoV-2.
Zost SJ, Gilchuk P, Case JB, Binshtein E, Chen RE, Nkolola JP, Schäfer A, Reidy JX, Trivette A, Nargi RS, Sutton RE, Suryadevara N, Martinez DR, Williamson LE, Chen EC, Jones T, Day S, Myers L, Hassan AO, Kafai NM, Winkler ES, Fox JM, Shrihari S, Mueller BK, Meiler J, Chandrashekar A, Mercado NB, Steinhardt JJ, Ren K, Loo YM, Kallewaard NL, McCune BT, Keeler SP, Holtzman MJ, Barouch DH, Gralinski LE, Baric RS, Thackray LB, Diamond MS, Carnahan RH, Crowe JE Jr. Zost SJ, et al. Among authors: kallewaard nl. Nature. 2020 Aug;584(7821):443-449. doi: 10.1038/s41586-020-2548-6. Epub 2020 Jul 15. Nature. 2020. PMID: 32668443 Free PMC article.
Structure and Function Analysis of an Antibody Recognizing All Influenza A Subtypes.
Kallewaard NL, Corti D, Collins PJ, Neu U, McAuliffe JM, Benjamin E, Wachter-Rosati L, Palmer-Hill FJ, Yuan AQ, Walker PA, Vorlaender MK, Bianchi S, Guarino B, De Marco A, Vanzetta F, Agatic G, Foglierini M, Pinna D, Fernandez-Rodriguez B, Fruehwirth A, Silacci C, Ogrodowicz RW, Martin SR, Sallusto F, Suzich JA, Lanzavecchia A, Zhu Q, Gamblin SJ, Skehel JJ. Kallewaard NL, et al. Cell. 2016 Jul 28;166(3):596-608. doi: 10.1016/j.cell.2016.05.073. Epub 2016 Jul 21. Cell. 2016. PMID: 27453466 Free PMC article.
34 results